| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of Medicine and Radiology University of Washington, Fred Hutchinson Cancer Research Center, Seattle, Washington
Dow Chemical Company, Indianapolis, Indiana
Correspondence: For correspondence or reprints contact: Janet Eary, MD, University of Washington Medical Center RC-08, 1959 NE Pacific St., Seattle, WA 98195.
ABSTRACT
Samarium-153-ethylenediaminetetramethylene phosphonic acid (EDTMP), a bone-seeking radiopharmaceutical, was given to prostate cancer patients in a dose escalation protocol for pain palliation to determine the maximally tolerated dose. Fifty-two patients with hormone refractory prostate cancer with bony metastases were treated with doses beginning at 0.5 mCi/kg (18.5 MBq/kg), escalating in 0.5-mCi (18.5 MBq) increments to 3.0 mCi/kg (111 MBq/kg). Pain response after treatment was assessed as well as hematologic and serum chemistry parameters. Pain palliation with a mean duration of 2.6 mo was present in 74% of the patients. Toxicity was exclusively hematologic at the highest dose levels. No infectious or bleeding complications occurred, with 45 of the 52 (86%) patients demonstrating complete hematologic recovery. Patients receiving higher doses had significantly greater reductions in serum prostate specific antigen and serum prostatic acid phosphatase levels. The patients receiving greater doses also showed a trend toward improved survival.
This article has been cited by other articles:
|
|
 |
|
  M. Chakraborty, E. K. Wansley, J. A. Carrasquillo, S. Yu, C. H. Paik, K. Camphausen, M. D. Becker, W. F. Goeckeler, J. Schlom, and J. W. Hodge The Use of Chelated Radionuclide (Samarium-153-Ethylenediaminetetramethylenephosphonate) to Modulate Phenotype of Tumor Cells and Enhance T Cell-Mediated Killing Clin. Cancer Res., July 1, 2008; 14(13): 4241 - 4249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. S. Bruland, S. Nilsson, D. R. Fisher, and R. H. Larsen High-Linear Energy Transfer Irradiation Targeted to Skeletal Metastases by the {alpha}-Emitter 223Ra: Adjuvant or Alternative to Conventional Modalities? Clin. Cancer Res., October 15, 2006; 12(20): 6250s - 6257s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Shah, W. E. Bolch, D. A. Rajon, P. W. Patton, and D. W. Jokisch A Paired-Image Radiation Transport Model for Skeletal Dosimetry J. Nucl. Med., February 1, 2005; 46(2): 344 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. J. Lewington Bone-Seeking Radionuclides For Therapy J. Nucl. Med., January 1, 2005; 46(1_suppl): 38S - 47S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Pandit-Taskar, M. Batraki, and C. R. Divgi Radiopharmaceutical Therapy for Palliation of Bone Pain from Osseous Metastases J. Nucl. Med., August 1, 2004; 45(8): 1358 - 1365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Smith, A. Navani, and S. M. Fishman Radiopharmaceuticals for palliation of painful osseous metastases American Journal of Hospice and Palliative Medicine, July 1, 2004; 21(4): 303 - 313. [Abstract] [PDF]
|
|
|
|
 |
|
 H. J. Siegel, J. V. Luck Jr, and M. E. Siegel Advances in Radionuclide Therapeutics in Orthopaedics J. Am. Acad. Ortho. Surg., January 1, 2004; 12(1): 55 - 64. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Giralt, W. Bensinger, M. Goodman, D. Podoloff, J. Eary, R. Wendt, R. Alexanian, D. Weber, D. Maloney, L. Holmberg, et al. 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials Blood, October 1, 2003; 102(7): 2684 - 2691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Morris and H. I. Scher Clinical Approaches to Osseous Metastases in Prostate Cancer Oncologist, April 1, 2003; 8(2): 161 - 173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Brenner, W. U. Kampen, C. Brummer, C. von Forstner, M. Zuhayra, N. Czech, C. Muhle, and E. Henze Bone Uptake Studies in Rabbits Before and After High-Dose Treatment with 153Sm-EDTMP or 186Re-HEDP J. Nucl. Med., February 1, 2003; 44(2): 247 - 251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Rajendran, J. F. Eary, W. Bensinger, L. D. Durack, C. Vernon, and A. Fritzberg High-Dose 166Ho-DOTMP in Myeloablative Treatment of Multiple Myeloma: Pharmacokinetics, Biodistribution, and Absorbed Dose Estimation J. Nucl. Med., October 1, 2002; 43(10): 1383 - 1390. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Anderson, G. A. Wiseman, A. Dispenzieri, C. A.S. Arndt, L. C. Hartmann, W. A. Smithson, B. P. Mullan, and O. S. Bruland High-Dose Samarium-153 Ethylene Diamine Tetramethylene Phosphonate: Low Toxicity of Skeletal Irradiation in Patients With Osteosarcoma and Bone Metastases J. Clin. Oncol., January 1, 2002; 20(1): 189 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. N. Serafini Therapy of Metastatic Bone Pain J. Nucl. Med., June 1, 2001; 42(6): 895 - 906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Brenner, W. U. Kampen, A. M. Kampen, and E. Henze Skeletal Uptake and Soft-Tissue Retention of 186Re-HEDP and 153Sm-EDTMP in Patients with Metastatic Bone Disease J. Nucl. Med., February 1, 2001; 42(2): 230 - 236. [Abstract] [Full Text]
|
|
|
|
|
|
A. Bishayee, D. V. Rao, S. C. Srivastava, L. G. Bouchet, W. E. Bolch, and R. W. Howell Marrow-Sparing Effects of 117mSn(4+)Diethylenetriaminepentaacetic Acid for Radionuclide Therapy of Bone Cancer J. Nucl. Med., December 1, 2000; 41(12): 2043 - 2050. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-F. Caubet, C. M. Moinpour, A. Troxel, L. C. Lovato, M. Eisenberger, B. A. Blumenstein, and E. D. Crawford Re: Quality of Life in Advanced Prostate Cancer: Results of a Randomized Therapeutic Trial • RESPONSE J Natl Cancer Inst, February 17, 1999; 91(4): 381 - 382. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
